Janus Henderson Group
ATRA icon

Janus Henderson Group’s Atara Biotherapeutics ATRA Stock Holding History

Janus Henderson Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,313
Closed -$95K – 2600
2023
Q1 		$95K Buy
1,313
+731
+126% +$70.9K ﹤0.01% 2620
2022
Q4 		$47.5K Hold
582
– – ﹤0.01% 2418
2022
Q3 		$55K Buy
582
+1
+0.2% +$112 ﹤0.01% 2114
2022
Q2 		$113K Hold
581
– – ﹤0.01% 2451
2022
Q1 		$135K Buy
+581
New +$185K ﹤0.01% 2517

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group's ATRA Position: Q2 2023 in Review

Janus Henderson Group sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 1,313 shares — an estimated $95K sold.

Janus Henderson Group first reported a position in ATRA in Q1 2022 and held it in 5 quarters. The position peaked at $135K in Q1 2022. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Janus Henderson Group reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 1,313 Atara Biotherapeutics shares in Q2 2023, an estimated $95K.
  • Janus Henderson Group first reported a position in Atara Biotherapeutics in Q1 2022 and held it in 5 quarters.
  • Janus Henderson Group's Atara Biotherapeutics position peaked at $135K in Q1 2022.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.